The purpose of this study is to investigate the effect of bexagliflozin in lowering
hemoglobin A1c (HbA1c) levels in patients with type 2 diabetes mellitus (T2DM) and increased
risk of cardiovascular adverse events.
The data from this study will be combined with the data from other bexagliflozin studies in a
meta-analysis of CV safety outcomes.